| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |